Cargando…
Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats
BACKGROUND: In a previous study, telmisartan suppressed aldosterone secretion in healthy cats but not in cats with primary hyperaldosteronism (PHA). HYPOTHESES: Telmisartan suppresses aldosterone secretion in middle‐aged healthy cat and cats with diseases that may result in secondary hyperaldosteron...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365049/ https://www.ncbi.nlm.nih.gov/pubmed/37246725 http://dx.doi.org/10.1111/jvim.16741 |
_version_ | 1785076969356918784 |
---|---|
author | Kurtz, Maxime Fabrès, Virginie Dumont, Renaud Chetboul, Valérie Chahory, Sabine Saponaro, Vittorio Trehiou, Emilie Poissonnier, Camille Passavin, Peggy Jondeau, Coline Bott, Matthieu Buronfosse, Thierry Benchekroun, Ghita |
author_facet | Kurtz, Maxime Fabrès, Virginie Dumont, Renaud Chetboul, Valérie Chahory, Sabine Saponaro, Vittorio Trehiou, Emilie Poissonnier, Camille Passavin, Peggy Jondeau, Coline Bott, Matthieu Buronfosse, Thierry Benchekroun, Ghita |
author_sort | Kurtz, Maxime |
collection | PubMed |
description | BACKGROUND: In a previous study, telmisartan suppressed aldosterone secretion in healthy cats but not in cats with primary hyperaldosteronism (PHA). HYPOTHESES: Telmisartan suppresses aldosterone secretion in middle‐aged healthy cat and cats with diseases that may result in secondary hyperaldosteronism, but not in those with PHA. ANIMALS: Thirty‐eight cats: 5 with PHA; 16 with chronic kidney disease (CKD), subclassified as hypertensive (CKD‐H) or non‐hypertensive (CKD‐NH); 9 with hyperthyroidism (HTH); 2 with idiopathic systemic arterial hypertension (ISH); and 6 healthy middle‐aged cats. METHODS: Prospective, cross‐sectional study. Serum aldosterone concentration, potassium concentration, and systolic blood pressure were measured before and 1 and 1.5 hours after PO administration of 2 mg/kg of telmisartan. The aldosterone variation rate (AVR) was calculated for each cat. RESULTS: No significant difference in the minimum AVR was observed among groups (median [quartile 1 (Q1); quartile 3 (Q3)]: 25 [0; 30]; 5 [−27; −75]; 10 [−6; −95]; 53 [19; 86]; 29 [5; 78]) for PHA, CKD, HTH, ISH, and healthy cats, respectively (P = .05). Basal serum aldosterone concentration (pmol/L) was significantly higher in PHA cats (median [Q1; Q3]: 2914 [2789; 4600]) than in CKD‐H cats (median [Q1; Q3]: 239 [189; 577], corrected P value = .003) and CKD‐NH cats (median [Q1; Q3]: 353 [136; 1371], corrected P value = .004). CONCLUSIONS AND CLINICAL IMPORTANCE: The oral telmisartan suppression test using a single dose of 2 mg/kg telmisartan did not discriminate cats with PHA from healthy middle‐aged cats or cats with diseases that may result in secondary hyperaldosteronism. |
format | Online Article Text |
id | pubmed-10365049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103650492023-07-25 Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats Kurtz, Maxime Fabrès, Virginie Dumont, Renaud Chetboul, Valérie Chahory, Sabine Saponaro, Vittorio Trehiou, Emilie Poissonnier, Camille Passavin, Peggy Jondeau, Coline Bott, Matthieu Buronfosse, Thierry Benchekroun, Ghita J Vet Intern Med SMALL ANIMAL BACKGROUND: In a previous study, telmisartan suppressed aldosterone secretion in healthy cats but not in cats with primary hyperaldosteronism (PHA). HYPOTHESES: Telmisartan suppresses aldosterone secretion in middle‐aged healthy cat and cats with diseases that may result in secondary hyperaldosteronism, but not in those with PHA. ANIMALS: Thirty‐eight cats: 5 with PHA; 16 with chronic kidney disease (CKD), subclassified as hypertensive (CKD‐H) or non‐hypertensive (CKD‐NH); 9 with hyperthyroidism (HTH); 2 with idiopathic systemic arterial hypertension (ISH); and 6 healthy middle‐aged cats. METHODS: Prospective, cross‐sectional study. Serum aldosterone concentration, potassium concentration, and systolic blood pressure were measured before and 1 and 1.5 hours after PO administration of 2 mg/kg of telmisartan. The aldosterone variation rate (AVR) was calculated for each cat. RESULTS: No significant difference in the minimum AVR was observed among groups (median [quartile 1 (Q1); quartile 3 (Q3)]: 25 [0; 30]; 5 [−27; −75]; 10 [−6; −95]; 53 [19; 86]; 29 [5; 78]) for PHA, CKD, HTH, ISH, and healthy cats, respectively (P = .05). Basal serum aldosterone concentration (pmol/L) was significantly higher in PHA cats (median [Q1; Q3]: 2914 [2789; 4600]) than in CKD‐H cats (median [Q1; Q3]: 239 [189; 577], corrected P value = .003) and CKD‐NH cats (median [Q1; Q3]: 353 [136; 1371], corrected P value = .004). CONCLUSIONS AND CLINICAL IMPORTANCE: The oral telmisartan suppression test using a single dose of 2 mg/kg telmisartan did not discriminate cats with PHA from healthy middle‐aged cats or cats with diseases that may result in secondary hyperaldosteronism. John Wiley & Sons, Inc. 2023-05-29 /pmc/articles/PMC10365049/ /pubmed/37246725 http://dx.doi.org/10.1111/jvim.16741 Text en © 2023 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC. on behalf of the American College of Veterinary Internal Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | SMALL ANIMAL Kurtz, Maxime Fabrès, Virginie Dumont, Renaud Chetboul, Valérie Chahory, Sabine Saponaro, Vittorio Trehiou, Emilie Poissonnier, Camille Passavin, Peggy Jondeau, Coline Bott, Matthieu Buronfosse, Thierry Benchekroun, Ghita Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats |
title | Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats |
title_full | Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats |
title_fullStr | Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats |
title_full_unstemmed | Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats |
title_short | Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats |
title_sort | prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats |
topic | SMALL ANIMAL |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365049/ https://www.ncbi.nlm.nih.gov/pubmed/37246725 http://dx.doi.org/10.1111/jvim.16741 |
work_keys_str_mv | AT kurtzmaxime prospectiveevaluationofatelmisartansuppressiontestasadiagnostictoolforprimaryhyperaldosteronismincats AT fabresvirginie prospectiveevaluationofatelmisartansuppressiontestasadiagnostictoolforprimaryhyperaldosteronismincats AT dumontrenaud prospectiveevaluationofatelmisartansuppressiontestasadiagnostictoolforprimaryhyperaldosteronismincats AT chetboulvalerie prospectiveevaluationofatelmisartansuppressiontestasadiagnostictoolforprimaryhyperaldosteronismincats AT chahorysabine prospectiveevaluationofatelmisartansuppressiontestasadiagnostictoolforprimaryhyperaldosteronismincats AT saponarovittorio prospectiveevaluationofatelmisartansuppressiontestasadiagnostictoolforprimaryhyperaldosteronismincats AT trehiouemilie prospectiveevaluationofatelmisartansuppressiontestasadiagnostictoolforprimaryhyperaldosteronismincats AT poissonniercamille prospectiveevaluationofatelmisartansuppressiontestasadiagnostictoolforprimaryhyperaldosteronismincats AT passavinpeggy prospectiveevaluationofatelmisartansuppressiontestasadiagnostictoolforprimaryhyperaldosteronismincats AT jondeaucoline prospectiveevaluationofatelmisartansuppressiontestasadiagnostictoolforprimaryhyperaldosteronismincats AT bottmatthieu prospectiveevaluationofatelmisartansuppressiontestasadiagnostictoolforprimaryhyperaldosteronismincats AT buronfossethierry prospectiveevaluationofatelmisartansuppressiontestasadiagnostictoolforprimaryhyperaldosteronismincats AT benchekrounghita prospectiveevaluationofatelmisartansuppressiontestasadiagnostictoolforprimaryhyperaldosteronismincats |